Risks and benefits of phase I liver dysfunction studies: should patients with severe liver dysfunction be included in these trials?

about

Risks and benefits of phase I liver dysfunction studies: should patients with severe liver dysfunction be included in these trials?

Item

http://www.wikidata.org/entity/Q47990284

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Risks and benefits of phase I ...... n be included in these trials?

@en

Risks and benefits of phase I ...... n be included in these trials?

@nl

type

Item

label

Risks and benefits of phase I ...... n be included in these trials?

@en

Risks and benefits of phase I ...... n be included in these trials?

@nl

prefLabel

Risks and benefits of phase I ...... n be included in these trials?

@en

Risks and benefits of phase I ...... n be included in these trials?

@nl

P1476

Risks and benefits of phase I ...... n be included in these trials?

@en

P2093

Anand Karnad

http://www.w3.org/2001/XMLSchema#string

Brian Hernandez

http://www.w3.org/2001/XMLSchema#string

Christos Fountzilas

http://www.w3.org/2001/XMLSchema#string

Devalingam Mahalingam

http://www.w3.org/2001/XMLSchema#string

Elizabeth Bowhay-Carnes

http://www.w3.org/2001/XMLSchema#string

Joel Michalek

http://www.w3.org/2001/XMLSchema#string

John Sarantopoulos

http://www.w3.org/2001/XMLSchema#string

Selena Stuart

http://www.w3.org/2001/XMLSchema#string

Steven Weitman

http://www.w3.org/2001/XMLSchema#string

Sukeshi Patel

http://www.w3.org/2001/XMLSchema#string

P2860

Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.

Transection of the oesophagus for bleeding oesophageal varices.

Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience

Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience.

Phase I trial outcomes in older patients with advanced solid tumours

Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.

Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy.

Effect of Renal Dysfunction on Toxicity in Three Decades of Cancer Therapy Evaluation Program-Sponsored Single-Agent Phase I Studies

Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432.

The Effect of Hepatic Impairment on Outcomes in Phase I Clinical Trials in Cancer Subjects.

P2888

s10637-017-0425-4

P304

386-391

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10637-017-0425-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28102465

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial